Allterum, FujiFilm begin development, scale-up of monoclonal antibodies for leukemia

By The Science Advisory Board staff writers

April 21, 2020 -- Allterum Therapeutics has received a $2.9 million product development grant from the Cancer Research and Prevention Institute of Texas to support preclinical development of monoclonal antibodies for leukemia.

Specifically, the funds will be used to support preclinical development of 4A10 antibody therapy for the treatment of pediatric patients suffering from T-cell acute lymphoblastic leukemia, according to the company. This technology was licensed from the U.S. National Cancer Institute.

In addition, the funding will be utilized to support the drug manufacturing scale-up currently underway in partnership with contract development and manufacturing organization Fujifilm Diosynth Biotechnologies, Allterum said.

Researchers reveal vulnerabilities of 'addicted' cancer cells
New findings about the mechanism by which some cancer cells can become "addicted" to glucose could lead to fresh approaches to targeted cancer therapies....
Researchers explore mutations to improve drug design
Drug resistance is a common challenge when designing therapeutics for cancers or diseases originating from bacteria or viruses. Researchers explored how...
Researchers work out the early steps that drive malignancy
Researchers from Yale University have identified cellular characteristics that lead to the early stages of malignancy. They state that in at least one...
CAR-T cell therapy research shows encouraging signs for mesothelioma patients
Every year, nearly 3,000 new cases of mesothelioma are diagnosed in the United States. While this is just a small percentage of overall cancer diagnoses,...
Is It Worth The Risk? Business Trends You Should Know About In The Bioprocessing Industry
The bioprocessing market is currently worth billions of dollars globally and is expected to increase 8.7 percent over the next five years. Pharmaceutical...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter